Navigation Links
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:6/19/2008

CALGARY, June 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy and Research Center, University of Texas Health Science Center in San Antonio, Texas (CTRC at UTHSCSA).

"REOLYSIN(R) is one of the more exciting targeted agents under development in oncology," said Dr. Frank Giles, Director of the Institute for Drug Development. "Our investigators within the CTRC at UTHSCSA are very excited to begin studying potential synergy with standard cytotoxic agents and are eager to expand our studies into other tumor types and utilizing other chemotherapy partner regimens."

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin.

Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase 2 trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancers.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase 1/2 and Phase 2 human trials using REOLYSIN(R), its pr
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Research and Markets ... DNA Diagnostics Market (Product types, Application, Technology, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. This new ... end users and Geography) Global Size, Industry Analysis, ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Phlo Corporation,(Pink Sheets: PHCP) (the "Company") announced today ... vitality beverage, AQISS(TM),will be significantly expanded with the ... beverage distributors in the San Francisco Bay Area., ... in principal with Morris,Distributing providing for the distribution ...
... July 14 Cepheid (Nasdaq:,CPHD) today announced that it ... June 30, 2008, on Thursday, July 24, 2008 after ... a management presentation at 1:30 p.m. Pacific,Time on Thursday, ... the live,webcast, please visit Cepheid,s website at http://www.cepheid.com/investors ...
... Liquids) will be held in Göteborg, Sweden on October 13-14, 2008 ... discussing commercialization of BTL. Technological advancements & worldwide growth of BTL ... insights on biomass to liquid industry prospect , ... ...
Cached Biology Technology:Phlo Affiliate Announces Significant Distribution Expansion In California 2Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast 2Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments? 2Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments? 3
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/16/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market announces that ... Smart Wallet, at the 13 th annual Future ... conference on the intersection of technology and the economy. ... founder and publisher of the Strategic News Service™, the ...
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... American Physical Society (APS) announces a new public access ... libraries in the United States full use of all ... to the first issue in 1893, a collection including ... this access at no cost to participating public libraries, ...
... D.C (July 29, 2010) While pundits write obituaries for ... already being felt across the world. We are losing species ... before seen. We need new tools and strategies ... and EcoAdapt are proud to announce the launch of their ...
... agriculture,s hardest workers as key pollinators for one-third of ... last half-century, with die-offs in recent years stumping scientists ... National Science Foundation (NSF) multi-institutional grant co-led by ... 10 natural history bee collections across the United States. ...
Cached Biology News:CAKE offers way forward for climate change adaptation 2New $1.5 million NSF grant to track bee declines and pollination 2
... Microarray Dot Blot Kits overcome this limitation ... over a wide range in low-density protein ... They are ideal for performing reverse-phase ... samples for the presence of low abundant ...
... easy-to-use kits for arraying proteins of ... common lab equipment. DiscoverLight Protein Array ... your protein, cell lysate or antibody ... kits include specially designed nitrocellulose membranes ...
Request Info...
... StabilZyme AP Conjugate Stabilizer is an ... bovine protein and other non-toxic stabilizing ... acid), pH 5.5 6.5. ... 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ...
Biology Products: